Mayo Clinic Hospital
- Type
- Teaching hospital
- Where
- Phoenix, AZ
- Medicare CCN
- 030103
- Received
- $22,206,278 in 1,727 records, 2025 ($2,606,941 general, $19,599,337 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 383 | $2,606,941 |
| 2025 | Research payment | 1,344 | $19,599,337 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,344 | $19,599,337 |
| Grant | 112 | $1,458,622 |
| Space rental or facility fees (teaching hospital only) | 175 | $767,390 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 21 | $209,779 |
| Education | 25 | $97,277 |
| Charitable Contribution | 2 | $38,000 |
| Long term medical supply or device loan | 41 | $34,851 |
| Debt forgiveness | 7 | $1,018 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $102,987 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $37,491 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $7,061 | Research payment | In-kind items and services | DOCETAXEL Drug, ONCOLOGY | A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista | 2025 |
| 2025-12-31 | Enterra Medical, Inc. | $6,120 | Research payment | Cash or cash equivalent | Navigate | 2025 | |
| 2025-12-31 | PFIZER INC. | $5,151 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | A PHASE 2 RANDOMIZED OPENLABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTI | 2025 |
| 2025-12-31 | ABBVIE INC. | $687 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-B | 2025 |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $546 | Research payment | In-kind items and services | Biograph mCT X-4R Device, MI - Nuclear Medicine (incl. PETNET & MIBR) | Software License Mayo MTP lesion linking prototype | 2025 |
| 2025-12-31 | Stryker Corporation | $452 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | Masimo Corporation | $189 | Long term medical supply or device loan | In-kind items and services | LiDCO Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $189 | Long term medical supply or device loan | In-kind items and services | LiDCO Device, Devices | 2025 | |
| 2025-12-31 | Masimo Corporation | $189 | Long term medical supply or device loan | In-kind items and services | LiDCO Device, Devices | 2025 | |
| 2025-12-31 | Alkermes, Inc. | $42 | Research payment | In-kind items and services | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-12-31 | Olympus America Inc. | $25 | Debt forgiveness | In-kind items and services | EVIS EXERA III COLONOVIDEOSCOPE Device, Gastroenterology | 2025 | |
| 2025-12-31 | Olympus America Inc. | $0 | Debt forgiveness | In-kind items and services | Device | 2025 | |
| 2025-12-30 | Genmab U.S., Inc. | $16,120 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | Real-world Outcomes in Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL) Treated with Epcoritamab | 2025 |
| 2025-12-30 | ABBVIE INC. | $8,131 | Research payment | Cash or cash equivalent | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate | 2025 | |
| 2025-12-30 | ABBVIE INC. | $6,990 | Research payment | Cash or cash equivalent | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants | 2025 | |
| 2025-12-30 | ABBVIE INC. | $6,600 | Research payment | Cash or cash equivalent | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intrave | 2025 | |
| 2025-12-30 | ABBVIE INC. | $4,002 | Grant | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-12-29 | Janssen Research & Development, LLC | $44,448 | Research payment | Cash or cash equivalent | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with | 2025 | |
| 2025-12-29 | Janssen Research & Development, LLC | $22,249 | Research payment | Cash or cash equivalent | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance | 2025 | |
| 2025-12-29 | PUMA BIOTECHNOLOGY, INC. | $6,900 | Research payment | Cash or cash equivalent | ALI-1201 | 2025 | |
| 2025-12-29 | Blue Earth Diagnostics | $5,065 | Research payment | In-kind items and services | Androgen Deprivation Therapy to Enrich PSMA Expressive to Improve Sensitivity of PSMA PET/CT: EnrichPSMA Trial | 2025 | |
| 2025-12-26 | Exelixis Inc. | $28,344 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in | 2025 | |
| 2025-12-25 | Novartis Pharmaceuticals Corporation | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LUTATHERA Drug, Oncology | 2025 | |
| 2025-12-24 | PFIZER INC. | $10,000 | Research payment | Cash or cash equivalent | A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED MULTICENTER STUDY TO EVALUATE THE CLINICAL EFFECT PHARMACODYNAMIC PHA | 2025 | |
| 2025-12-24 | PFIZER INC. | $8,428 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06823859 I | 2025 | |
| 2025-12-24 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-24 | ABBVIE INC. | $673 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2025 | |
| 2025-12-23 | Amgen Inc. | $15,000 | Grant | Cash or cash equivalent | REPATHA Biological, Cardiovascular | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $8,740 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $8,067 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $6,829 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $6,345 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $5,330 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Genentech USA, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Tecentriq Biological, BioOncology | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $4,828 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $4,818 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $4,806 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Olympus America Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Single Use Aspiration Needle NA-U200H Device, Endotherapy | 2025 | |
| 2025-12-23 | Olympus America Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Single Use Aspiration Needle NA-U200H Device, Endotherapy | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $1,203 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $810 | Research payment | Cash or cash equivalent | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva | 2025 | |
| 2025-12-23 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-22 | Ionis Pharmaceuticals, Inc. | $5,500 | Research payment | Cash or cash equivalent | An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Tra | 2025 | |
| 2025-12-22 | Ionis Pharmaceuticals, Inc. | $1,500 | Research payment | Cash or cash equivalent | An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Tra | 2025 | |
| 2025-12-22 | Ionis Pharmaceuticals, Inc. | $1,100 | Research payment | Cash or cash equivalent | An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Tra | 2025 | |
| 2025-12-22 | Ionis Pharmaceuticals, Inc. | $382 | Research payment | Cash or cash equivalent | An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Tra | 2025 | |
| 2025-12-19 | Blue Earth Diagnostics | $83,246 | Research payment | Cash or cash equivalent | Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With L | 2025 | |
| 2025-12-19 | Gyrus ACMI, Inc. | $24,855 | Research payment | Cash or cash equivalent | iTIND System Device, Urology Gynecology | A post-market, prospective, randomized, controlled, multicenter international study to assess the safety of the Temporar | 2025 |
| 2025-12-18 | Novocure Inc. | $41,210 | Research payment | Cash or cash equivalent | EF-41/?KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblas | 2025 | |
| 2025-12-18 | SANOFI US SERVICES INC. | $1,000 | Research payment | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU | 2025 |
| 2025-12-17 | VERTEX PHARMACEUTICALS INCORPORATED | $4,900 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,628 | Research payment | Cash or cash equivalent | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-16 | Ionis Pharmaceuticals, Inc. | $10,107 | Research payment | Cash or cash equivalent | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacod | 2025 | |
| 2025-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,156 | Research payment | Cash or cash equivalent | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-16 | Ionis Pharmaceuticals, Inc. | $8,567 | Research payment | Cash or cash equivalent | AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY OF EPLONTERSEN ION682884 IN PATIENTS WITH TRANSTHYRETINMEDIAT | 2025 | |
| 2025-12-16 | Exelixis Inc. | $2,600 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in | 2025 | |
| 2025-12-16 | Boston Scientific Corporation | $1,826 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | OCCLUDE | 2025 |
| 2025-12-16 | Boston Scientific Corporation | $1,761 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | OCCLUDE | 2025 |
| 2025-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,170 | Research payment | Cash or cash equivalent | A Phase II, randomised, placebo-controlled, double-blind, parallel group, efficacy and safety study of at least 48 weeks | 2025 | |
| 2025-12-16 | Ionis Pharmaceuticals, Inc. | $400 | Research payment | Cash or cash equivalent | An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients With Hereditary Tra | 2025 | |
| 2025-12-15 | TransMedics, Inc. | $17,000 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCSHEART-OHP-II | 2025 |
| 2025-12-15 | Kaneka Medical America LLC | $16,350 | Research payment | Cash or cash equivalent | Apheresis Machine Device, Nephrology | Post Market Surveillance Study | 2025 |
| 2025-12-12 | Incyte Corporation | $7,500 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-12 | ABBVIE INC. | $5,532 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-12-12 | Incyte Corporation | $5,500 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-12 | Incyte Corporation | $3,900 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-12 | Alnylam Pharmaceuticals Inc. | $3,315 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) Wit | 2025 |
| 2025-12-12 | Incyte Corporation | $2,860 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-12 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-12 | Incyte Corporation | $1,400 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-12 | Alnylam Pharmaceuticals Inc. | $600 | Research payment | Cash or cash equivalent | ONPATTRO Drug, Genetic Disease | Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) Wit | 2025 |
| 2025-12-11 | PFIZER INC. | $249,999 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-11 | Janssen Biotech, Inc. | $26,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-11 | ABBVIE INC. | $16,400 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractor | 2025 | |
| 2025-12-11 | Genmab U.S., Inc. | $8,250 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $7,130 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Photocure Inc | $7,047 | Research payment | Cash or cash equivalent | CYSVIEW Drug, ONCOLOGY | Blue Light Cystoscopy With Cysview Registry | 2025 |
| 2025-12-11 | Boston Scientific Corporation | $5,000 | Grant | Cash or cash equivalent | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $4,580 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Boston Scientific Corporation | $3,250 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-11 | Novartis Pharmaceuticals Corporation | $3,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-12-11 | Genentech, Inc. | $2,608 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 | |
| 2025-12-11 | H. Lundbeck A S | $1,938 | Research payment | Cash or cash equivalent | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $250 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $94 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,431 | Research payment | Cash or cash equivalent | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administer | 2025 | |
| 2025-12-10 | Cook Incorporated | $2,500 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | Alkermes, Inc. | $1,729 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-10 | Alkermes, Inc. | $715 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-09 | Janssen Biotech, Inc. | $20,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-09 | Phathom Pharmaceuticals, Inc. | $4,850 | Education | Cash or cash equivalent | VOQUEZNA Drug, Gastroenterology | 2025 | |
| 2025-12-08 | GENZYME CORPORATION | $22,360 | Research payment | Cash or cash equivalent | FIH SAR446523 GDPRC5D ADCC Enhanced R/R in Multiple Myeloma SC | 2025 | |
| 2025-12-08 | BeOne Medicines USA, Inc. | $6,102 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BG | 2025 | |
| 2025-12-08 | Merck Sharp & Dohme LLC | $2,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-12-08 | GENZYME CORPORATION | $1,400 | Research payment | Cash or cash equivalent | WAYRILZ Drug, Immunology | A Phase 3, multicenter, randomized, double-bline, placebo controlled, parallel-group study with an open-label period and | 2025 |
| 2025-12-08 | Incyte Corporation | $181 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $172 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $137 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Alkermes, Inc. | $106 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-08 | Incyte Corporation | $101 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $88 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $72 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $49 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Alkermes, Inc. | $37 | Research payment | In-kind items and services | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK | 2025 | |
| 2025-12-08 | Incyte Corporation | $34 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $16 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-08 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia | 2025 | |
| 2025-12-06 | Olympus Corporation of the Americas | $111,275 | Grant | In-kind items and services | HANAROSTENT Esophagus TTS(CCC) Device, Endotherapy | 2025 | |
| 2025-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,100 | Research payment | Cash or cash equivalent | Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given or | 2025 | |
| 2025-12-05 | ERBE USA Inc | $1,000 | Education | Cash or cash equivalent | vio3 Device, Gastroenterology | 2025 | |
| 2025-12-04 | ABBVIE INC. | $51,251 | Research payment | Cash or cash equivalent | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants | 2025 | |
| 2025-12-04 | ABBVIE INC. | $16,573 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractor | 2025 | |
| 2025-12-04 | Genentech, Inc. | $15,218 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants | 2025 | |
| 2025-12-04 | F. Hoffmann-La Roche AG | $15,000 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-04 | ABBVIE INC. | $11,443 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-12-04 | F. Hoffmann-La Roche AG | $10,360 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-04 | H. Lundbeck A S | $9,693 | Research payment | Cash or cash equivalent | A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) | 2025 | |
| 2025-12-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,493 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-12-04 | Blue Earth Diagnostics | $5,065 | Research payment | In-kind items and services | Androgen Deprivation Therapy to Enrich PSMA Expressive to Improve Sensitivity of PSMA PET/CT: EnrichPSMA Trial | 2025 | |
| 2025-12-04 | F. Hoffmann-La Roche AG | $4,100 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-04 | Genentech USA, Inc. | $4,002 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Polivy Biological, BioOncology | 2025 | |
| 2025-12-04 | F. Hoffmann-La Roche AG | $4,000 | Research payment | Cash or cash equivalent | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan | 2025 | |
| 2025-12-04 | ABBVIE INC. | $3,843 | Research payment | Cash or cash equivalent | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participa | 2025 | |
| 2025-12-04 | Regeneron Pharmaceuticals, Inc. | $2,293 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-04 | ABBVIE INC. | $22 | Research payment | Cash or cash equivalent | BOTOX Biological, FACIAL AESTHETICS | BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind | 2025 |
| 2025-12-03 | E.R. Squibb & Sons, L.L.C. | $57,352 | Research payment | Cash or cash equivalent | A phase I, multicenter, open-label study of CC-98633, BCMA targeted NEX-T chimeric antigen receptor (CAR) T cells, in su | 2025 | |
| 2025-12-03 | AstraZeneca Pharmaceuticals LP | $15,000 | Research payment | Cash or cash equivalent | DATROWAY Biological, Oncology | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by A | 2025 |
| 2025-12-03 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $3,250 | Grant | Cash or cash equivalent | LifeVest Device, Electromedical and Electrotherapeutic Apparatus | 2025 | |
| 2025-12-03 | Ionis Pharmaceuticals, Inc. | $632 | Research payment | Cash or cash equivalent | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacod | 2025 | |
| 2025-12-03 | Alkermes, Inc. | $500 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-03 | Alkermes, Inc. | $137 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of | 2025 | |
| 2025-12-02 | Cook Incorporated | $13,500 | Grant | In-kind items and services | EVOLUTION Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Incorporated | $13,500 | Grant | In-kind items and services | EVOLUTION Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Medical LLC | $12,430 | Education | Cash or cash equivalent | 2025 | ||
| 2025-12-02 | Cook Incorporated | $9,000 | Grant | In-kind items and services | HEMOSPRAY Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Incorporated | $9,000 | Grant | In-kind items and services | HEMOSPRAY Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Incorporated | $4,000 | Grant | In-kind items and services | DUETTE Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Incorporated | $645 | Grant | In-kind items and services | SAVARY GILLIARD Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Incorporated | $430 | Grant | In-kind items and services | SAVARY GILLIARD Device, Endoscopy | 2025 | |
| 2025-12-02 | Cook Incorporated | $270 | Grant | In-kind items and services | HEMOSPRAY Device, Endoscopy | 2025 | |
| 2025-12-01 | Merck Sharp & Dohme LLC | $74,759 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2025 |
| 2025-12-01 | Exelixis Inc. | $44,623 | Research payment | Cash or cash equivalent | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in | 2025 | |
| 2025-12-01 | Janssen Research & Development, LLC | $31,356 | Research payment | Cash or cash equivalent | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance | 2025 | |
| 2025-12-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-01 | Daiichi Sankyo Inc. | $219 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $155 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $150 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $150 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $87 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $74 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $62 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $50 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $48 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $47 | Research payment | In-kind items and services | Open-label dose-finding trial to explore safety, pharmacokinetics, pharmacodynamics, and efficacy of BI 3706674 given or | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $41 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $41 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $37 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $31 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $29 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $25 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $24 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $20 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $17 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $15 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $12 | Research payment | Cash or cash equivalent | Vanflyta Drug, ONCOLOGY | AC220-168 | 2025 |
| 2025-12-01 | Daiichi Sankyo Inc. | $8 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $8 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-12-01 | Daiichi Sankyo Inc. | $4 | Research payment | Cash or cash equivalent | DS7300-202 | 2025 | |
| 2025-11-30 | Enterra Medical, Inc. | $16,510 | Research payment | Cash or cash equivalent | Navigate | 2025 | |
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $20,524 | Research payment | Cash or cash equivalent | A study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With P | 2025 | |
| 2025-11-26 | ABBVIE INC. | $17,414 | Research payment | Cash or cash equivalent | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants | 2025 |
The latest 200 records of 1,727.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Phoenix, AZ, county Maricopa County, AZ, state Arizona; placed by its city name.
| Measure | Place (city or town) Phoenix, AZ | County Maricopa County, AZ | State Arizona |
|---|---|---|---|
| Population B01003 | 1,642,323 | 4,559,748 | 7,378,838 |
| Population, 2020 census P1 | 1,608,139 | 4,420,568 | 7,151,502 |
| Median age B01002 | 34.9 | 37.6 | 39.0 |
| Under 18 B01001 | 23.6% | 22.5% | 21.6% |
| 65 and over B01001 | 12.2% | 16.3% | 18.9% |
| Households B11001 | 610,442 | 1,730,696 | 2,856,081 |
| Foreign born B05002 | 19.0% | 14.5% | 13.0% |
| Median household income B19013 | $81,332 | $89,300 | $79,964 |
| Median family income B19113 | $94,886 | $105,249 | $95,980 |
| Per capita income B19301 | $41,981 | $46,183 | $42,503 |
| Poverty rate B17001 | 13.7% | 11.0% | 12.5% |
| Unemployment rate B23025 | 5.0% | 4.5% | 5.1% |
| Civilian labor force B23025 | 887,179 | 2,373,071 | 3,598,840 |
| Mean commute (minutes) B08013 | 25.6 | 26.0 | 25.4 |
| Bachelor's degree or higher B15003 | 33.6% | 36.7% | 33.3% |
| Housing units B25001 | 653,065 | 1,884,334 | 3,192,839 |
| Owner-occupied B25003 | 57.3% | 65.2% | 67.4% |
| Renters B25003 | 42.7% | 34.8% | 32.6% |
| Median home value B25077 | $420,700 | $452,800 | $394,500 |
| Median gross rent B25064 | $1,582 | $1,708 | $1,543 |
| White, not Hispanic B03002 | 40.6% | 52.5% | 52.6% |
| Black B03002 | 7.4% | 5.4% | 4.4% |
| Hispanic or Latino B03002 | 42.0% | 31.2% | 31.4% |
| Asian B03002 | 4.0% | 4.5% | 3.5% |
| American Indian and Alaska Native B03002 | 1.4% | 1.3% | 3.2% |
Economy now FRED unemployment 4.9% in Sep 2026 (4.4% a year earlier); per capita personal income $68,373 in 2025, up 31% in five years (+5.7% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Phoenix, AZ.
Comments